Core Insights - The current stage of the bio-ink industry is marked by the successful large-scale application of second-generation bioactive materials, particularly GelMA, which has improved cell survival rates from 60% to over 90% after printing, facilitating clinical translation of simple tissues like skin and cartilage [1][6] - The Chinese bio-ink market is projected to reach approximately 82.16 million yuan in 2024, reflecting a year-on-year growth of 4.85% [1][6] - The industry faces two major bottlenecks: the inability to construct capillary networks with diameters ≤10μm, which hampers the long-term survival of printed organs, and significant variability in batch stability affecting standardization and clinical application [1][6] Industry Overview - Bio-ink is a core material for 3D bioprinting, composed of hydrogels, biomolecules (like collagen and hyaluronic acid), live cells, and growth factors, characterized by biocompatibility, rheology, and dynamic tunability [2][3] - The bio-ink industry supply chain includes natural polymers (e.g., alginate, collagen) and synthetic polymers (e.g., PEG, PCL), with downstream applications in tissue engineering and organ printing [3][4] Market Size - The bio-ink market in China is expected to grow to 82.16 million yuan in 2024, with a growth rate of 4.85% [1][6] - The global regenerative medicine market is projected to reach $35.82 billion in 2024, growing at 21.75%, with bio-ink emerging as one of the fastest-growing segments [6] Key Companies - Major players in the bio-ink industry include Huaxia Siyin, which has completed the first medical-grade bio-ink documentation in China, and Guangzhou Maipu, which has developed a range of bio-inks and achieved significant clinical applications [8][9] - Hangzhou Jienofei has established itself as a leading supplier of biomedical 3D printing solutions, holding over 200 patents and participating in national key research projects [8] Industry Development Trends - Future breakthroughs in vascularization technology are expected to focus on constructing microvascular networks, with advancements in dual-photon polymerization and composite material strategies [9][10] - The establishment of standardized immunogenicity control and evaluation systems is crucial for scaling production and ensuring consistent clinical outcomes [10][12] - Enhancements in batch stability through intelligent production systems and real-time monitoring are anticipated to improve the consistency of bio-ink quality [11][12]